Dermira Inc (NASDAQ:DERM) – Research analysts at Leerink Swann increased their FY2018 EPS estimates for shares of Dermira in a research report issued to clients and investors on Wednesday. Leerink Swann analyst S. Fernandez now forecasts that the biopharmaceutical company will post earnings per share of ($3.55) for the year, up from their prior forecast of ($3.79). Leerink Swann has a “Outperform” rating and a $48.00 price target on the stock. Leerink Swann also issued estimates for Dermira’s FY2019 earnings at ($4.78) EPS, FY2020 earnings at ($3.09) EPS and FY2021 earnings at ($0.86) EPS.
Several other analysts also recently weighed in on the company. Cantor Fitzgerald set a $45.00 target price on Dermira and gave the company a “buy” rating in a research note on Monday, January 15th. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. BidaskClub downgraded Dermira from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Guggenheim restated a “buy” rating and set a $30.00 target price on shares of Dermira in a research note on Thursday, December 14th. Finally, Mizuho decreased their target price on Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. Dermira presently has an average rating of “Hold” and an average target price of $42.17.
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.09). Dermira had a negative return on equity of 41.22% and a negative net margin of 992.18%.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in Dermira by 15.6% in the 2nd quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock valued at $114,294,000 after acquiring an additional 529,405 shares in the last quarter. Jennison Associates LLC raised its holdings in Dermira by 0.3% in the 3rd quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after acquiring an additional 7,746 shares in the last quarter. Vanguard Group Inc. raised its holdings in Dermira by 9.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after acquiring an additional 125,157 shares in the last quarter. Voya Investment Management LLC raised its holdings in Dermira by 61.4% in the 2nd quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock valued at $35,783,000 after acquiring an additional 467,356 shares in the last quarter. Finally, State Street Corp raised its holdings in Dermira by 38.4% in the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after acquiring an additional 228,093 shares in the last quarter. 99.47% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $27.52, for a total value of $137,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,258 shares of company stock valued at $985,873. 13.30% of the stock is owned by corporate insiders.
WARNING: “Leerink Swann Analysts Boost Earnings Estimates for Dermira Inc (DERM)” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3148464/leerink-swann-analysts-boost-earnings-estimates-for-dermira-inc-derm.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.